{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"8.17","value":"4.0"},{"groupId":"OG001","lowerLimit":"0.5","upperLimit":"8.0","value":"3.99"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"Time of maximal concentration (Tmax) at steady state following 15 days of QD dosing","dispersionType":"Full Range","groups":[{"description":"Part 1 and Part 2: Patients received a starting dose of 300 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG000","title":"Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD"},{"description":"Part 1 and Part 2: Patients received a starting dose of 400 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG001","title":"Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD"}],"paramType":"MEDIAN","populationDescription":"Patients enrolled in Part 1 and Part 2 with a starting dose of 300 or 400 mg QD and available samples for PK","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 15","title":"Time of Maximal Concentration (Tmax) at Steady State","type":"SECONDARY","unitOfMeasure":"h"}